Sinotherapeutics (SH:688247) Zheng Quan Ri Bao Wang·2026-01-15 09:43Core Viewpoint - The company focuses on high-end generic drugs and integrated CRO/CMO services, while accelerating the development of modified new drugs [1] Group 1: High-End Generic Drugs - The company is deeply engaged in the high-end generic drug sector [1] - It aims to transition from a generic drug company to a hybrid specialty pharmaceutical company [1] Group 2: Innovative Drug Development - The first self-developed modified new drug project, XT-0043, has shown excellent safety and efficacy in Phase II clinical trials and has successfully reached clinical endpoints [1] - The company is fully advancing the initiation and implementation of Phase III clinical trials based on Phase II clinical data [1] Group 3: Injection Drug Development - The company is actively enhancing its research and development capabilities in the injection drug field [1] - It is accelerating the construction of complex injection drug formulation technology platforms, including lyophilized injections, liposomes, and long-acting injections [1]